ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 1409
Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial
Abstract Number: 1410
Tocilizumab Improves Left Ventricular Mass and Cardiac Output in Patients With Rheumatoid Arthritis. A Cohort Study
Abstract Number: 1411
The Peroxisome Proliferator Activated Receptor-gamma pioglitazone Decreases Cardiovascular Risk and Disease Activity In Patients With Rheumatoid arthritis 
Abstract Number: 1412
Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial – Treat 2b – Of Tregalizumab In Rheumatoid Arthritis
Abstract Number: 1413
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
Abstract Number: 1414
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate
Abstract Number: 1415
Safety and Effectiveness Of Abatacept In 3985 Japanese Patients With Rheumatoid Arthritis; Japan All-Cases Post-Marketing Surveillance
Abstract Number: 1416
Safety and Efficacy Of Subcutaneous Golimumab In Chinese Patients With Active Rheumatoid Arthritis Despite MTX Therapy: Results From a Randomized, Placebo-Controlled, Phase 3 Trial
Abstract Number: 1417
Lack Of Correlation Between Golimumab Exposure and Selected Safety Events Following Intravenous Or Subcutaneous Administration In An Integrated Analysis Of Phase 3 Data Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Or Ankylosing Spondylitis
Abstract Number: 1418
Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
Abstract Number: 1419
Mode Of Action Change Not Necessary After Failing The First Tumornecrosisfactor Inhibitor: Preliminary Results Of a Randomized Controlled Trial
Abstract Number: 1420
Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Abstract Number: 1421
Treatment Responses and Their Predictors Of Abatacept In Biologic naïve Patients With Rheumatoid Arthritis; Data Form Abroad Study
Abstract Number: 1422
Efficacy and Safety Of a Novel Disease-Modifying Antirheumatic Drug, Iguratimod, As Add-On Therapy For Patients With Rheumatoid Arthritis
Abstract Number: 1423
The Influence Of Body Mass Index On The Efficacy Of Tumor Necrosis Factor Blocking Therapy For Rheumatoid Arthritis
Abstract Number: 1424
Persistence On Single Disease Modifying Anti-Rheumatic Drug Therapy In US Veterans With Rheumatoid Arthritis Is Extremely Rare
Abstract Number: 1425
Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
Abstract Number: 1426
Inhibition Of Spermidine/Spermine N1-Acetyltransferase Activity – a New Therapeutical Concept In Rheumatoid Arthritis
Abstract Number: 1427
Discovery and Characterization Of ABT-122, An Anti-TNF/IL-17 DVD-Ig™ Molecule As a Potential Therapeutic Candidate For Rheumatoid Arthritis
Abstract Number: 1428
The Safety and Efficacy Of Tocilizumab Subcutaneous In Combination With Traditional Dmards In Patients With Moderate To Severe Rheumatoid Arthritis Up To 48 Weeks (BREVACTA)
Abstract Number: 1429
Adiponectin Levels Are Increased After Tocilizumab Therapy Among Adults With Rheumatoid Arthritis: Results From The Measure Study
Abstract Number: 1430
Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients
Abstract Number: 1431
Algorithms Using Genome-Wide SNP Analysis For Prediction Of Efficacy and Adverse Events Of Abatacept Using Two Population Samples From Multiple Medical Cohorts
Abstract Number: 1432
The Rate Of Serious Infections Remains Stable In Patients With Multiple Retreatments In Real life : Data From The “Auto Immunity and Rituximab” (AIR) Registry
Abstract Number: 1433
Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis
Abstract Number: 1434
Assessing Janus Kinase inhibitor’s Place In Therapy In Established Rheumatoid Arthritis Patients – From a Simplified Indirect Comparison Versus Tumor Necrosis Factor Inhibitors To a Bayesian Probability Of Response – The Value Of Transparency
Abstract Number: 1435
Effectiveness Of TNF-á Inhibitor Therapy Does Not Differ Between Elderly and Younger Patients With Rheumatoid Arthritis: Results From The Corrona Registry
Abstract Number: 1436
Early Changes In a Multi-Biomarker Disease Activity Score After Starting Adalimumab Treatment Predict Change In MRI Inflammation At 6 Months
Abstract Number: 1437
Clinical and Radiographic Outcomes At Two Years and The Effect Of Tocilizumab Discontinuation Following Sustained Remission In The Second Year Of The ACT-RAY Study
Abstract Number: 1438
Comparative Effectiveness Of Rituximab Vs. Subsequent Anti-Tumor Necrosis Factor In Patients With Rheumatoid Arthritis With Prior Exposure To TNFi
Abstract Number: 1439
Safety, Pharmacokinetics, and Pharmacodynamics Of SAN-300, a Novel Monoclonal Antibody Against Very Late Antigen-1: Results Of a Phase 1 Study In Healthy Volunteers and Patients With Active Rheumatoid Arthritis
Abstract Number: 1440
Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Abstract Number: 1441
Predictive Factors Of Response To Tocilizumab In Patients With Active Rheumatoid Arthritis
Abstract Number: 1442
Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with  Rheumatoid Arthritis Treated In Routine Care. Results From The Nationwide Danish Danbio Registry
Abstract Number: 1443
Is The Risk Of Tumor Necrosis Factor Inhibitor-Induced Lupus The Same With Monoclonal Antibodies and Soluble Receptor? A Case/Non-Case Study In a Nationwide Pharmacovigilance Database
Abstract Number: 1444
Immunogenicity Induced By Tumor Necrosis Factor Antagonists In Chronic Inflammatory Arthropathies: Retrospective Study In Clinical Practice Conditions
Abstract Number: 1445
GEMS Audit: An Evaluation Of Routine Use Of Subcutaneous Methotrexate In Rheumatoid Arthritis
Abstract Number: 1446
The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate
Abstract Number: 1447
Success Rate Of 5-Or-More-Week Extended-Interval Therapy With Tocilizumab In Rheumatoid Arthritis Patients In Routine Practice
Abstract Number: 1448
Drug Retention Rates Of Biologic Monotherapies For Patients With Rheumatoid Arthritis In Daily Clinical Practice; Using Multicenter Registry In Japan
Abstract Number: 1449
Comparison Of Effects Of Standard- and Low-Dose Etanercept On Inflammatory Synovitis In Rheumatoid Arthritis Patients As Assessed By Ultrasonography
Abstract Number: 1450
Safety Of Resuming The Tumor Necrosis Factor Antagonists Therapy In Patients Who Developed Tuberculosis After Use Of Tumor Necrosis Factor Antagonists
Abstract Number: 1451
Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable In The United States
Abstract Number: 1452
An Early Economic Evaluation Of Personalized Treatment With Rituximab By Prediction Of Effectiveness Using The Interferon Type I Signature In Rheumatoid Arthritis
Abstract Number: 1453
Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA® DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Abstract Number: 1454
The Effects Of The Spleen Tyrosine Kinase Inhibitor Fostamatinib On Ambulatory Blood Pressure In Patients With Active Rheumatoid Arthritis – Results Of The Oskira Ambulatory Blood Pressure Monitoring Trial
Abstract Number: 1455
Comparison Of Serum Matrix Metalloproteinase-3 Levels In Rheumatoid Arthritis After Treatment With Adalimumub Or Abatacept For 24 Weeks
Abstract Number: 1456
Golimumab Levels, Anti-Drug Antibodies and Clinical Response In Rheumatoid Arthritis Patients At 28 Week Of Follow-Up
Abstract Number: 1457
Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice
Abstract Number: 1458
Rates Of Switching and Healthcare Costs Associated With Switching Biologic Disease-Modifying Antirheumatic Drugs In a Commercial Population: Evidence From Real-World Observational Studies
Abstract Number: 1459
Multiple Cytokine Profiling Predicts The Effectiveness Of Switching Biologics In Rheumatoid Arthritis
Abstract Number: 1460
10 Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes
Abstract Number: 1461
Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population
Abstract Number: 1462
Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort
Abstract Number: 1463
Dietary Impact On Treatment Results Of Methotrexate In Patients With Rheumatoid Arthritis
Abstract Number: 1464
Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)
Abstract Number: 1465
Adherence To The Recommended Dosing Regimen Of Abatacept In The Real-World Setting In The Action Study: Is There a Dose-Creep In Overweight Patients?
Abstract Number: 1466
Survival On Treatment Of The Second Line Biologic Therapy: Switch Or Swap Strategy?
Abstract Number: 1467
Adalimumab In Combination With High and Low Dose-Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study
Abstract Number: 1468
Reasons For Discontinuation Of Biologic Agents In Rheumatoid Arthritis Patients
Abstract Number: 1469
Therapeutic Strategy In Patients With Rheumatoid Arthritis and Insufficient Response To a 1st Anti-TNF: Results of the Multicenter Randomized Controlled “ROC” Trial
Abstract Number: 1470
Anti-Tumour Necrosis Factor Alpha Therapy Reduces Platelet Reactivity and Is Associated With Improved Insulin Sensitivity In Patients With Inflammatory Arthritis
Abstract Number: 1471
Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 1472
Discontinuation Rates Of Tocilizumab Therapy In Rheumatoid Arthritis Patients In a Nonacademic Clinical Setting
Abstract Number: 1473
Anti-Tumor Necrosis Factor α Therapy (Etanercept) Plus Methotrexate Lowers Serum Amyloid A Levels To a Greater Extent Than Triple Oral Disease Modifying Anti-Rheumatic Drug Therapy In Early Rheumatoid Arthritis Subjects
Abstract Number: 1475
Subcutaneous Delivery Of Methotrexate Is Associated With Improved Treatment Survival Compared To Oral Administration For The Initial Treatment Of Patients With Early Rheumatoid Arthritis
Abstract Number: 1476
Effectiveness Of Etanercept In Elderly Patients With Rheumatoid Arthritis: A Single Center Retrospective Study
Abstract Number: 1477
A Novel Method Predicting Good Response Using Only Background Clinical Data In RA Patients Treated With Infliximab
Abstract Number: 1478
The Prevalence Of Biological Monotherapy Among Rheumatoid Arthritis Patients In Denmark: Results From The Danish Nationwide Danbio Registry
Abstract Number: 1479
Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX
Abstract Number: 1480
Prevalance Of Rare Variants In Methotrexate Pathway Genes: Implications From The National Heart Lung Blood Institute (NHLBI) Exome Sequencing Project
Abstract Number: 1481
Negative Effect Of Glucocorticoids Persistence Therapy On Porosity In Rheumatoid Arthritis Patients Treated With TNFα Blockers
Abstract Number: 1482
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Abstract Number: 1483
Physician and Patient Characteristics Associated With The Decision To Treat Rheumatoid Arthritis Patients With Biologic Monotherapy In Usual Care Settings
Abstract Number: 1484
Treatment With The Glucagon-Like Peptide-1 Analogue Liraglutide Is Associated With Amelioration Of Disease Activity In a Prospective Cohort Study Of Patients With Inflammatory Arthritis
Abstract Number: 1485
RNA Transcripts From Peripheral Blood Mononuclear Cells As Predictors Of Clinical Responsiveness In Rheumatoid Arthritis Subjects Treated With Abatacept

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.